Physician

David S Friedenberg, D.O.

According to 2025 Medicare claims, David Friedenberg, D.O. (NPI: 1710975016) practices nephrology in the Manchester-Nashua, NH market, with the plurality of this provider's patient population coming from Hillsborough, NH. This provider's primary affiliated billing organization is NEPHROLOGY ASSOCIATES, P. A. (NPI: 1073630752; TIN: 020344800) and primary practice location at 03104-2919. Friedenberg is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Friedenberg's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 402 traditional Medicare patients, billed 1,286 HCPCS/CPT codes, and received $168,067 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,311 prescription claims across 239 beneficiaries totaling $213,481 in drug costs, led by Jardiance (Empagliflozin). DME data shows 111 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $239,885 and ending at $213,481. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	610	2,019	$216,253
2016	581	2,221	$226,486
2017	552	1,999	$226,070
2018	514	1,943	$227,406
2019	490	1,850	$221,882
2020	426	1,536	$185,711
2021	439	1,634	$222,256
2022	451	1,554	$212,802
2023	426	1,607	$183,619
2024	402	1,286	$168,067

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	190	1,539	$239,885
2016	187	1,438	$312,034
2017	186	1,184	$265,758
2018	195	1,219	$185,271
2019	200	1,217	$204,337
2020	188	1,182	$172,028
2021	214	1,317	$181,608
2022	213	1,310	$236,775
2023	224	1,310	$226,545
2024	239	1,311	$213,481

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	128	$3,602
2016	N/R	196	$5,604
2017	N/R	181	$6,971
2018	N/R	226	$8,714
2019	N/R	213	$8,051
2020	N/R	214	$9,809
2021	N/R	188	$7,188
2022	N/R	124	$3,215
2023	N/R	138	$2,508
2024	N/R	111	$1,544

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	57	57	$157
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	205	283	$93
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	47	82	$62
90935	Hemodialysis procedure with physician evaluation	57	128	$55
81000	Manual urinalysis test with examination using microscope, non-automated	50	50	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	60	3,096	$59,591
Velphoro	Sucroferric Oxyhydroxide	26	840	$51,324
Farxiga	Dapagliflozin Propanediol	22	1,920	$31,370
Sevelamer Carbonate	Sevelamer Carbonate	56	2,990	$4,898
Chlorthalidone	Chlorthalidone	172	15,256	$3,231

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	35	$659
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	26	$326
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	24	$306
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	26	$253

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for David S. Friedenberg, D.O.?

Tedicare shows public-source Medicare data for David S. Friedenberg, D.O. (NPI 1710975016), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David S. Friedenberg, D.O. have ACO affiliation data?

David S. Friedenberg, D.O. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to David S. Friedenberg, D.O.?

David S. Friedenberg, D.O. is linked to NEPHROLOGY ASSOCIATES, P. A. (billing NPI 1073630752) in the available physician profile data.

Does David S. Friedenberg, D.O. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.